What are the challenges associated with EEG source analysis in the field of epilepsy? How might EEG source analysis affect the frontline of epilepsy care? Dr. Stefan Rampp (University Hospital Erlangen, Germany) discusses how BESA’s portfolio could help to overcome these challenges and much more.
Browsing: Epilepsy and seizure
Using fluorescent tags, a team of researchers discovered a novel mechanism for synaptic plasticity that may have pharmacological applications in the treatment of epilepsy.
NHS England have approved the use of cannabis-based medicines for the first time. Epidyolex can now be prescribed to children with severe epilepsy syndromes and Sativex can be prescribed to individuals with multiple sclerosis.
A new therapeutic concept, which utilizes dynorphin-based gene therapy, has been developed and could suppress seizures at their site of origin and on demand.
Epidyolex® has gained approval from the European Commission for seizures associated with Lennox–Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
A promising new study could provide an early warning system to enable people with epilepsy to know when they are at risk of having a seizure.
Researchers have recently found that the brains of children with severe epilepsy can be compensated by rewiring regions of the visual cortex after surgery.
A Phase III study has shown that cannabidiol can reduce seizures by almost half in children with Dravet syndrome, a rare type of severe epilepsy.